| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel;
Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8078, Unité Paris Sud, Institut Paris Sud Cytokines, Hospital Marie Lannelongue, Le Plessis Robinson, France; and
Open University of Israel, Raanana, Israel
Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG), are autoimmune disorders in which the acetylcholine receptor (AChR) is the major autoantigen. Microarray technology was used to identify new potential drug targets for treatment of myasthenia that would reduce the need for the currently used nonspecific immunosuppression. The chemokine IFN-
-inducible protein 10 (IP-10; CXCL10), a CXC chemokine, and its receptor, CXCR3, were found to be overexpressed in lymph node cells of EAMG rats. Quantitative real-time PCR confirmed these findings and revealed up-regulated mRNA levels of another chemoattractant that activates CXCR3, monokine induced by IFN- (Mig; CXCL9). TNF-
and IL-1
, which act synergistically with IFN- to induce IP-10, were also up-regulated. These up-regulations were observed in immune response effector cells, namely, lymph node cells, and in the target organ of the autoimmune attack, the muscle of myasthenic rats, and were significantly reduced after suppression of EAMG by mucosal tolerance induction with an AChR fragment. The relevance of IP-10/CXCR3 signaling in myasthenia was validated by similar observations in MG patients. A significant increase in IP-10 and CXCR3 mRNA levels in both thymus and muscle was observed in myasthenic patients compared with age-matched controls. CXCR3 expression in PBMC of MG patients was markedly increased in CD4+, but not in CD8+, T cells or in CD19+ B cells. Our results demonstrate a positive association of IP-10/CXCR3 signaling with the pathogenesis of EAMG in rats as well as in human MG patients.
This article has been cited by other articles:
|
|
 |
|
  C Ospelt, M Kurowska-Stolarska, M Neidhart, B A Michel, R E Gay, S Laufer, and S Gay The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands Ann Rheum Dis, April 1, 2008; 67(4): 524 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ubiali, S. Nava, V. Nessi, R. Longhi, G. Pezzoni, R. Capobianco, R. Mantegazza, C. Antozzi, and F. Baggi Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats J. Immunol., February 15, 2008; 180(4): 2696 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Su, R. S. Grajewski, D. Luger, R. K. Agarwal, P. B. Silver, J. Tang, J. Tuo, C.-C. Chan, and R. R. Caspi Altered Chemokine Profile Associated with Exacerbated Autoimmune Pathology under Conditions of Genetic Interferon-{gamma} Deficiency Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4616 - 4625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pasvolsky, S. W. Feigelson, S. S. Kilic, A. J. Simon, G. Tal-Lapidot, V. Grabovsky, J. R. Crittenden, N. Amariglio, M. Safran, A. M. Graybiel, et al. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets J. Exp. Med., July 9, 2007; 204(7): 1571 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. FEFERMAN, R. ARICHA, R. MENON, M. C. SOUROUJON, S. BERRIH-AKNIN, and S. FUCHS DNA Microarray in Search of New Drug Targets for Myasthenia Gravis Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hansen, N. J. Bernard, C. Q. Nie, and L. Schofield NK Cells Stimulate Recruitment of CXCR3+ T Cells to the Brain during Plasmodium berghei-Mediated Cerebral Malaria J. Immunol., May 1, 2007; 178(9): 5779 - 5788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Qian, H. An, Y. Yu, S. Liu, and X. Cao TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation Blood, April 15, 2007; 109(8): 3308 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Le Panse, G. Cizeron-Clairac, J. Bismuth, and S. Berrih-Aknin Microarrays Reveal Distinct Gene Signatures in the Thymus of Seropositive and Seronegative Myasthenia Gravis Patients and the Role of CC Chemokine Ligand 21 in Thymic Hyperplasia J. Immunol., December 1, 2006; 177(11): 7868 - 7879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roosterman, T. Goerge, S. W. Schneider, N. W. Bunnett, and M. Steinhoff Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev, October 1, 2006; 86(4): 1309 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meraouna, G. Cizeron-Clairac, R. L. Panse, J. Bismuth, F. Truffault, C. Tallaksen, and S. Berrih-Aknin The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis Blood, July 15, 2006; 108(2): 432 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Sheng, S. Hu, H. T. Ni, T. N. Rowen, J. R. Lokensgard, and P. K. Peterson TNF-{alpha}-induced chemokine production and apoptosis in human neural precursor cells J. Leukoc. Biol., December 1, 2005; 78(6): 1233 - 1241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
